# Bevacizumab Beyond Progression (BBP)

> **NCT01740258** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 68 (actual)

## Conditions studied

- Malignant Glioma
- Grade 4 Malignant Glioma
- Glioblastoma
- Gliosarcoma

## Interventions

- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01740258
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2019-11-14
- **Final completion:** 2019-11-14
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740258, "Bevacizumab Beyond Progression (BBP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01740258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*